Study of AZD2811 + durvalumab in ES-SCLC - TAZMAN

Study identifier:D6132C00001

ClinicalTrials.gov identifier:NCT04745689

EudraCT identifier:2020-004091-18

CTIS identifier:2024-511887-10-00

Recruitment Complete

Official Title

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer

Medical condition

Small-Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide

Sex

All

Actual Enrollment

31

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 23 Feb 2021
Primary Completion Date: 18 Jun 2022
Estimated Study Completion Date: 29 Nov 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria